Cyclophosphamide/Prednisone/ThalidomideLack of efficacy following off-label use

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2016卷 / 1期

关键词：

D O I：

10.1007/s40278-024-62649-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：156 / 156

相关论文

共 50 条

[31] OcrelizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2025, 2055 (1) : 283 - 283
[32] MethylprednisoloneLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1902 (1) : 280 - 280
[33] Multiple drugsLack of efficacy and thyroiditis following off-label use
Reactions Weekly, 2023, 1988 (1) : 124 - 124
[34] EribulinLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1921 (1) : 135 - 135
[35] RuxolitinibLack of efficacy following off-label use: case report
Reactions Weekly, 2024, 2039 (1) : 502 - 502
[36] OmalizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1956 (1) : 409 - 409
[37] LorazepamLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1919 (1) : 354 - 354
[38] ImiquimodLack of efficacy following off-label use: case report
Reactions Weekly, 2022, 1920 (1) : 254 - 254
[39] AzithromycinLack of efficacy following an off-label use: case report
Reactions Weekly, 2022, 1915 (1) : 92 - 92
[40] VedolizumabLack of efficacy following off-label use: case report
Reactions Weekly, 2023, 1938 (1) : 1250 - 1250

← 1 2 3 4 5 →